SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-007376
Filing Date
2023-03-13
Accepted
2023-03-10 17:40:10
Documents
12
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20230310.htm   iXBRL 8-K 63834
  Complete submission text file 0000950170-23-007376.txt   185705

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tnya-20230310_pre.xml EX-101.PRE 11445
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tnya-20230310.xsd EX-101.SCH 2494
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tnya-20230310_lab.xml EX-101.LAB 13887
6 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20230310_htm.xml XML 4907
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 23725042
SIC: 2836 Biological Products, (No Diagnostic Substances)